Conference Coverage

This channel highlights DAIC's coverage of numerous key cardiology and medical imaging conferences each year. These include ACC, AHA, ASE, ASNC, EuroPCRECR, HIMSS, HRS, RSNA, SCAI, SCCT, TCT, and VIVA.

PARTNER 3 trial shows positive results for Sapien 3 in low-risk surgical patients. #ACC20 #ACC2020 #Sapien3 #TAVR
Feature | Heart Valve Technology | March 30, 2020
March 30, 2020 — Low-risk patients undergoing transcatheter aortic valve repair (TAVR) at two years did just as well...
News | Heart Valve Technology | March 29, 2020
March 29, 2020 — Worse than expected outcomes were found for survival and quality of life among patients undergoing...
Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) #ACC20/#WCCardio
News | Heart Failure | March 29, 2020
March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational...
Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session. #ACC20 #ACC2020
Feature | Heart Valve Technology | March 29, 2020 | Dave Fornell, Editor
March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve...
POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation  (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020
News | Atrial Fibrillation | March 29, 2020
March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing...
Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial. #ACC20 #ACC2020

Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial.

News | Pharmaceuticals | March 28, 2020 | Dave Fornell, Editor
March 28. 2020 — Among adults with heterozygous familial hypercholesterolemia, those who received the drug inclisiran...
Find more news from ACC 2020.Women carry heavier burden of chest pain, but less artery narrowing according to data in a substudy of the ISCHEMIA Trial. #ACC20 #ACC2020 #ISCHEMIA

Women carry heavier burden of chest pain, but less artery narrowing, according to data in a substudy from the ISCHEMIA Trial. 
 

News | Womens Cardiovascular Health | March 28, 2020
March 28, 2020 — Women with coronary artery disease that reduces blood flow and oxygen to the heart muscle (ischemia)...
Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis. #ACC20 #ACC2020
News | Heart Failure | March 28, 2020
March 28, 2020 — New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of...
Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to...
The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

News | Peripheral Artery Disease (PAD) | March 28, 2020
March 28, 2020 — People with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with...
News | Coronavirus (COVID-19) | March 27, 2020
March 27, 2020 — The European Society of Cardiology (ESC) has created a novel coronavirus resource page with...
SCAI cancelled due to COVID-19, SARS-CoV-2, coronavirus. #COVID19 #coronavirus #coronavirusupdate #SARScov2
News | Coronavirus (COVID-19) | March 23, 2020
March 23, 2020 — As the novel coronavirus (COVID-19, SARS-cov-2) continues to spread, the Society for Cardiovascular...
Medicare, CMS, calls for cancelling or postponing all elective or non-essential medical procedures, test and surgeries due to COVID-19. #COVID19 #SARcov2 #coronavirus #cardiology
Feature | Coronavirus (COVID-19) | March 20, 2020 | Dave Fornell, Editor
March 20, 2020 — The Centers for Medicare and Medicaid Services (CMS) announced March 18, 2020, that all elective...
Videos | Coronavirus (COVID-19) | March 20, 2020
An interview with Ehtisham Mahmud, M.D., FSCAI, chief, Division of Cardiovascular Medicine, executive director of...
Medicare will pay for telehealth virtual doctor visits during the duration of the coronavirus COVID-19 outbreak.
News | Cardiovascular Business | March 17, 2020
March 17, 2020 — The Trump Administration today announced expanded Medicare telehealth coverage that will enable...